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Summary
What is already known on this topic?
It is estimated that 13 million people in the United States have latent
tuberculosis infection (LTBI). This large number of potential LTBI cases
poses a challenge for successful tuberculosis control and elimination.
What is added by this report?
We examined a novel, collaborative care model using community pharma-
cies as additional access points for LTBI treatment for patients using com-
bination weekly therapy with isoniazid and rifapentine and directly ob-
served therapy for 12 weeks.
What are the implications for public health practice?
High completion rates and safe administration of LTBI treatment can be
achieved in the community pharmacy setting.
Abstract
Introduction
The objective of this study was to evaluate a novel collaborative
care  model  using community  pharmacies  as  additional  access
points for latent tuberculosis infection (LTBI) treatment for pa-
tients using combination weekly therapy with isoniazid and ri-
fapentine (3HP) plus directly observed therapy for 12 weeks.
Methods
This prospective pilot study included adult patients diagnosed with
LTBI. Patients were eligible for study participation if they spoke
English or Spanish and were followed by the New Mexico Depart-
ment of Health (NM DOH). Patients were excluded if they were
pregnant, receiving concomitant HIV antiretroviral therapy, or had
contraindications to 3HP due to allergy or drug interactions. Com-
munity pharmacy sites included chain, independent, and hospital
outpatient pharmacies in Albuquerque and Santa Fe, New Mexico.
Results
A total of 40 patients initiated treatment with 3HP and were in-
cluded. Most were female (55%) and had a mean age of 46 years
(standard deviation, 12.6 y). A total of 75.0% of patients com-
pleted LTBI treatment with 3HP in a community pharmacy site.
Individuals of Hispanic ethnicity were more likely to complete
treatment (76.7% vs 40.0%, P = .04). Most patients (60%; n = 24)
reported experiencing an adverse drug event (ADE) with 3HP
therapy. Patients who completed treatment were less likely to ex-
perience an ADE than patients who discontinued treatment (50.0%
vs 90.0%, P = .03). Pharmacists performed 398 LTBI treatment
visits (40 initial visits, 358 follow-up visits), saving the NM DOH
approximately 143 hours in patient contact time.
Conclusion
High completion rates and safe administration of LTBI treatment
can be achieved in the community pharmacy setting.
Introduction
Tuberculosis (TB) is a curable disease, yet it is the tenth leading
cause of death worldwide, ranking above HIV (1). TB disease res-
ulted in an estimated 1.3 million deaths worldwide in 2017 (1).
The World Health Organization has outlined a framework for TB
elimination in low-incidence countries such as the United States
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(2). Included in the TB elimination strategy is the identification
and treatment of latent tuberculosis infection (LTBI) to prevent
progression to and transmission of active disease (2). Treatment of
LTBI decreases illness and death associated with active TB dis-
ease (3) and is associated with less medication toxicity and cost
compared with active TB disease treatment (4–6). It is estimated
that 13 million people have LTBI in the United States (7). This
large number of potential LTBI cases poses a serious public health
challenge for successful TB control and elimination. Using com-
munity pharmacies is a possible strategy to expand access for test-
ing and treatment.
In 2011, because of nursing resource limitations at the New Mex-
ico Department of Health (NM DOH), tuberculin skin testing was
made available in New Mexico community pharmacies (8). As of
2016, more than 200 New Mexico pharmacists had been trained to
provide this public health service, which provides testing access
for patients in small city locations and has been widely used by
patients across the state (8,9). In 2017, the NM DOH TB program
wanted to expand access to patients by also providing LTBI treat-
ment in the community pharmacy setting.
In 2012 the NM DOH transitioned from LTBI treatment with iso-
niazid monotherapy to weekly combination therapy with isoniazid
plus rifapentine (3HP). This short 12-week combination regimen
is associated with higher completion rates and lower rates of hep-
atotoxicity (10,11). However, the 3HP regimen is still associated
with medication toxicity, drug–drug interactions, and nonadher-
ence. Providing this once-weekly regimen in a community phar-
macy setting is one potential option to address these issues.
Completion rates for LTBI vary considerably in the literature, ran-
ging from 35%–90%, with higher completion rates generally re-
ported with shorter treatment regimens (10,12–17). Predictors for
noncompletion include unstable housing, tobacco use, alcohol use,
adverse drug events (ADEs), older age, patient location, poverty,
and non-Hispanic ethnicity (14,18–21).
Data evaluating the use of pharmacists in the treatment of LTBI
are limited (22–25). However, the available studies have reported
high completion rates when a pharmacist was included in treat-
ment management. Tavitian et al reported high completion rates
(93%) associated with a pharmacist-managed clinic for treatment
of LTBI with isoniazid monotherapy in health care workers (22).
Carter et al also reported high LTBI completion rates (94%) with a
pharmacist-run clinic using monotherapy with either rifampin or
isoniazid for refugee patients (25). To our knowledge, administra-
tion of LTBI treatment in the community pharmacy setting has
never been evaluated.
The primary objective of this study was to evaluate a novel and
collaborative care model using community pharmacy sites to sup-
port increased patient access to LTBI treatment using combina-
tion weekly therapy with isoniazid 900 mg plus rifapentine 900
mg for 12 weeks. Secondary objectives were evaluation of treat-
ment completion rates and ADEs.
Methods
The University of New Mexico Health Sciences Research Protec-
tion Office institutional review board approved the study protocol.
This prospective pilot study included adult patients ≥18 years of
age who were diagnosed with LTBI by a physician at  the NM
DOH. Patients were eligible for study participation if they spoke
English or Spanish and were followed by the NM DOH offices in
Albuquerque or Santa Fe, New Mexico. Patients also had to be
able to take LTBI treatment with weekly combination therapy with
900 mg of rifapentine and 900 mg of isoniazid for 12 weeks. Pa-
tients were excluded if they were pregnant, receiving concomitant
HIV antiretroviral therapy, or had contraindications to 3HP due to
allergy or drug interaction. Eligible patients with newly diagnosed
LTBI who were seen at the Santa Fe or Albuquerque departments
of health from February 2017 through April 2018 were given the
choice to receive usual care through the NM DOH or participate in
the study, receiving 3HP with directly observed therapy (DOT) at
a participating community pharmacy of their choice.
Before consent, patients were provided with a list of 9 possible
pharmacy locations (3 pharmacies in Santa Fe and 6 pharmacies in
Albuquerque) and their hours of operation. Study investigators
identified and contacted 10 pharmacies as potential  pilot  sites
based on geographical distribution and site diversity. Nine phar-
macies agreed to participate. Community pharmacy sites included
chain,  independent,  and hospital  outpatient pharmacies,  in Al-
buquerque and Santa  Fe,  New Mexico (NM).  The pharmacies
were geographically distributed throughout the cities to provide a
variety of pharmacy locations for study participants. Patients were
allowed to choose only 1 pharmacy location and could not switch
locations after consent. No study incentive was offered to patients.
Medications were provided to patients at no charge regardless of
study participation. Women of childbearing age were counseled to
use a barrier birth control method before enrollment and with ri-
fapentine initiation.  Study investigators consented patients for
study participation at the NM DOH clinics. Baseline laboratory
tests (liver function tests, complete blood counts, comprehensive
metabolic panel, and HIV with opt-out option) were drawn at the
NM DOH before 3HP initiation. Patient demographics, comorbid-
ities, and additional TB risk factors (1) were collected to charac-
terize the patient population being served.
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Before implementation, participating pharmacies (range, 1–3 phar-
macists per pharmacy) attended (either in person or via videocon-
ferencing) a 2-hour accredited continuing education training on
LTBI treatment held at the University of New Mexico. NM DOH
nursing personnel at the participating department of health loca-
tions were also included in the training program. The NM DOH
TB program medical director, the NM DOH TB program man-
ager/TB nurse consultant, and an infectious diseases pharmacist
provided the training for community pharmacies. The infectious
diseases pharmacist trained additional pharmacists who joined the
project at a later date, using the same training materials.
After consenting a patient for study participation, the patient’s pre-
scriptions for rifapentine 900 mg (4 tablets) and isoniazid 900 mg
(3 tablets), to be taken weekly with DOT, were faxed to the parti-
cipating pharmacy with 11 refills (12 doses total of 3HP). The TB
physician could adjust  the dose for  weight.  The TB physician
could also order pyridoxine (vitamin B6) if appropriate.
The participating pharmacies were responsible for acquiring and
storing the LTBI medications according to the state law and phar-
macy  policy.  The  cost  of  the  medication  varied  for  each  site
(~$25–30/week). Grant funds provided pharmacies adequate com-
pensation to cover the cost of the medication and pharmacist time.
In addition, telephonic interpreter services, also provided through
grant funding, were available for Spanish-speaking patients at all
pharmacy locations.
Participating pharmacies followed the NM DOH nursing protocol
for LTBI treatment with DOT. Patients picked up their weekly
doses at the community pharmacy. At each visit the pharmacist
would 1) complete a drug–drug interaction evaluation, 2) screen
the patient for 3HP treatment toxicity, 3) screen the patient for
symptoms of active TB disease, 4) provide the LTBI treatment
medication, and 5) watch the patient take the medication (DOT).
Screening questions were adopted from the DOH LTBI treatment
protocol. If a patient developed signs and symptoms suggestive of
liver or hematologic toxicity, the pharmacist contacted the DOH
TB program nurse manager and instructed the patient to hold the
medications. Potentially serious ADEs were reported to the NM
DOH TB Program and reviewed by the TB physician. Reportable
potential ADEs were jaundice, persistent nausea or vomiting, ab-
dominal pain, easy bruising or bleeding, and changes in urine or
stool color. Medications could be resumed or discontinued after
evaluation by the NM DOH TB program’s medical director. Pa-
tients could discontinue treatment at the community pharmacy and
complete treatment through the NM DOH if closer follow-up was
required by the TB physician. Treatment was considered complete
if patients received 12 doses. To be consistent with DOH comple-
tion rate reporting calculations, patients who did not start therapy
were not included in the data analysis.
Continuous variables were described by using measures of central
tendency (mean, standard deviation [SD]), and binary and categor-
ical variables were described by using the number of nonmissing
and missing observations and the frequency and percentage of re-
sponses.  Patients  receiving  treatment  were  categorized  into  2
groups: 1) those receiving the complete 12 doses of treatment and
2) those receiving partial treatment. Statistical differences between
the 2 groups were determined using the Student’s t test for con-
tinuous variables (pooled method for equal variances, Satterth-
waite method for unequal variances) and Fisher exact test for bin-
ary and categorical variables. All tests were 2-sided and used a
significance level of P < .05. SAS statistical software version 9.4
(SAS Institute, Inc) was used to perform analyses.
Results
Of the 41 patients who consented to participate in the study dur-
ing  the  evaluation  period,  40  initiated  treatment  and were  in-
cluded in the data analysis (Figure). Thirty patients received LTBI
treatment at an Albuquerque community pharmacy, and 10 pa-
tients received LTBI treatment at a Santa Fe community phar-
macy. Most patients were female (55%; n = 22), Hispanic white
(37.5%; n = 15), and had an average age of 46 years (SD, 12.6 y)
(Table 1).
Figure. Flow diagram for patient enrollment, study on using a collaborative
care model to treat LTBI, New Mexico, 2017–2018. Abbreviation: LTBI, latent
tuberculosis infection.
Of 40 patients who initiated treatment, 75% (n = 30) completed
LTBI treatment with 3HP at  1 of the participating community
pharmacy sites. Seven patients discontinued 3HP because of po-
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tential ADEs, and 3 patients were lost to follow-up. A higher per-
centage of patients who completed treatment were of Hispanic eth-
nicity compared with patients who discontinued treatment (76.7%
vs 40.0%, P = .04) (Table 1). Other demographic characteristics,
including age, sex, and substance use (ie, tobacco or alcohol) did
not differ between patients who completed or discontinued LTBI
treatment. Most patients (60%; n = 24) reported experiencing an
ADE with 3HP therapy (Table 2). The most common ADEs repor-
ted were dark urine (27.5%; n = 11), excessive fatigue (22.5%; n =
9), and nausea/vomiting (22.5%; n = 9). Differences between the
groups were significant with regard to ADEs. Fewer patients who
completed treatment experienced any ADE compared with pa-
tients who discontinued treatment (50% vs 90%, P = .03). ADEs
that patients who completed treatment experienced less often than
those who discontinued treatment were excessive fatigue (13.3%
vs 50.0%, P = .03) and nausea/vomiting (13.3% vs 50.0%, P =
.03). Potentially serious ADEs were reported to the NM DOH TB
Program and reviewed by the TB physician. In 7 cases (17.1%) it
was determined that the patient should discontinue 3HP treatment.
Of the 7 patients who discontinued 3HP therapy at a community
pharmacy site, 1 was able to complete LTBI therapy with another
LTBI regimen through the NM DOH, bringing the overall comple-
tion rate to 77.5%. No cases of active tuberculosis or death were
reported during the study period. The average number of doses re-
ceived by patients who discontinued therapy at a community phar-
macy was 3.8 (SD, 2.3).
Pharmacists performed 398 LTBI treatment visits (40 initial visits,
358 follow-up visits) during the evaluation period. Pharmacists re-
corded the estimated time for initial and follow-up visits for 26 pa-
tients.  The average time for  an initial  visit  was 25 (SD, 10.1)
minutes. The average time for follow up visits was 22 (SD, 9.7)
minutes.  The  initiative  saved  the  NM DOH more  than  8,876
minutes (148 hours) in patient visit time. Most patients (62.5%; n
= 25) lived 5 miles or less from the pharmacy where they received
3HP treatment (Table 3).
Discussion
This is the first study to evaluate the feasibility of providing LTBI
treatment  with  DOT  in  a  community  pharmacy  setting  as  a
strategy to improve patient access in collaboration with a state
health department. We demonstrated that 3HP can be safely ad-
ministered in a community pharmacy collaborative care setting
and result in high rates of LTBI treatment completion (75% in
community pharmacy setting; 77.5% overall). Our LTBI comple-
tion rate was similar to rates reported by the NM DOH. In 2017,
the NM DOH reported that 374 patients in NM were determined to
have LTBI at a DOH clinic location (26); 167 patients initiated
treatment, 107 (64.1%) completed LTBI treatment (New Mexico
Department of Health Tuberculosis Prevention Program, 2017, un-
published data). High rates of completion in the community phar-
macy setting are likely a result of a variety of accessible phar-
macy locations, extended operating hours, and no requirement for
scheduled appointments.
In our cohort we found that Hispanic patients were more likely to
complete  LTBI treatment  compared with  non-Hispanics.  This
finding is consistent with those of prior studies (14,19–21,28,29),
but its cause is unclear. However, perception of disease risk has
been previously reported as a predictor for LTBI treatment com-
pletion (30), which this study did not assess. These patients may
have had an increased perception of risk if they or their family
members were born in TB-endemic areas.
We reported high rates of potential ADEs (n = 24; 60%). ADEs,
including nausea/vomiting and fatigue, were associated with non-
completion of LTBI treatment in this study. This finding is also
consistent with prior studies (18,21). Most potential medication
side effects reported with 3HP were not serious and may have
been due to other causes. Most patients were managed through the
pharmacy with direct communication and collaboration with the
DOH. This resulted in treatment completion in 17 of the 24 pa-
tients (71%) that experienced a potential ADE. Pharmacists were
able to ensure pyridoxine (vitamin B6) supplementation when ap-
propriate and discuss options to address nausea. Addressing poten-
tial ADEs in a community pharmacy setting is an opportunity to
increase completion rates before losing patients to follow-up.
WHO describes the importance of accessible and free TB services
in their elimination framework (2). Community pharmacies may
be able to offer an additional accessible setting to provide LTBI
treatment. To achieve TB elimination, it is important to increase
access to treatment in ways that are convenient for patients while
also relieving a portion of the burden from the DOH. A total of 41
of the 67 patients who received treatment chose to participate in
this study and receive treatment at a community pharmacy site,
highlighting patient interest in this treatment setting. With an in-
crease in available community pharmacy sites,  it  is  likely that
more patients will have the opportunity to complete treatment.
Data from this pilot project provide important information about
LTBI treatment administered in the community pharmacy setting.
However, our study has limitations. First, results cannot be gener-
alized outside of New Mexico. This was a pilot study with a small
sample in 2 large city settings in New Mexico, which is largely
rural and has health care professional shortages and patient so-
cioeconomic barriers. In addition, only a small subset of the total
number of pharmacies in the state participated in the study. To
minimize this limitation, we included pharmacies that were geo-
graphically  distributed,  including both  independent  and chain
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pharmacies. We would not expect the study results to differ signi-
ficantly if all New Mexico pharmacies offering this public health
service had participated.  In addition,  we only evaluated LTBI
treatment with 3HP plus DOT. Another consideration is that this
project was supported by a grant, which covered the cost of 3HP
medication provided in the community pharmacy. If this public
health service is to be sustainably offered to patients at no charge,
a  mechanism will  need to  be  identified  to  address  the  cost  of
providing this service in the community pharmacy setting. Finally,
the success of this program can be attributed to the collaboration
with  the  DOH, in  which training and expert  consultation  was
provided.
LTBI treatment with 3HP plus DOT can be safely administered in
a community pharmacy collaborative care setting and offers op-
portunity for improved access to care for patients. High rates of
completion in a community pharmacy setting are likely a result of
increased access to care through neighborhood pharmacy loca-
tions, extended operating hours, and no requirement for scheduled
appointments. The largest barrier to LTBI treatment completion
was ADEs. Pharmacists can help identify and manage potential
ADEs in the community pharmacy setting, which may minimize
loss to follow-up.
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Tables
Table 1. Treatment Completion Rates of Participants (N = 40), by Demographic Characteristics, Study on Using a Collaborative Care Model to Treat LTBI, New Mex-
ico, 2017–2018
Demographic Characteristic Valuea
Completed Treatmentb
(n = 30)
Discontinued Treatment
(n = 10) P Valueb
Male sex 18 (45.0) 15 (50) 3 (30) .46
Mean age, y (SD) 46.0 (12.6) 45.6 (14.0) 47.2 (7.5) .73
Mean BMI, kg/m2 (SD) 28.6 (6.1) 28.0 (5.6) 30.2 (7.5) .37
Hispanic ethnicity
Yes 27 (67.5) 23 (76.7) 4 (40)
.04No 12 (30.0) 7 (23.3) 5 (50)
Unknown 1 (2.5) 0 1 (10)
Race/ethnicity
Hispanic white 15 (37.5) 12 (40.0) 3 (30)
.008
Hispanic other 12 (30.0) 11 (36.7) 1 (10)
Non-Hispanic white 7 (17.5) 6 (20.0) 1 (10)
Non-Hispanic black 2 (5.0) 1 (3.3) 1 (10)
Non-Hispanic Asian 3 (7.5) 0 3 (30)
Unknown 1 (2.5) 0 1 (10)
Birth country
United States 10 (25.0) 7 (23.3) 3 (30)
.70Non-US 29 (72.5) 22 (73.3) 7 (70)
Unknown 1 (2.5) 1 (3.3) 0
Substance use
Alcohol 10 (25.0) 7 (23.3) 3 (30) .69
Tobacco 14 (35.0) 12 (40.0) 2 (20) .45
Comorbiditiesb
Diabetes 7 (17.5) 6 (20.0) 1 (10) .66
Asthma 2 (5.0) 2 (6.7) 0 >.99
End-stage renal disease 4 (10.0) 4 (13.3) 0 .56
Abbreviations: BMI, body mass index; LTBI, latent tuberculosis infection; SD, standard deviation.
a Values are no. (%) unless otherwise indicated.
b Determined using t test for mean differences and Fisher exact test for frequency differences.
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Table 2. Reported Adverse Drug Events of Patients (N = 40), by Patient Treatment Completion Status, Study on Using a Collaborative Care Model to Treat LTBI, New
Mexico, 2017–2018
Type of ADE No. (%)
Completed Treatmenta
(n = 30)
Discontinued Treatment
(n = 10)
P ValueaNo. (%)
Any 24 (60.0) 15 (50.0) 9 (90) .03
Dark urine 11 (27.5) 8 (26.7) 3 (30) >.99
Nausea/vomiting 9 (22.5) 4 (13.3) 5 (50) .03
Excessive fatigue 9 (22.5) 4 (13.3) 5 (50) .03
Appetite loss 6 (15.0) 3 (10.0) 3 (30) .15
Abdominal discomfort 6 (15.0) 3 (10.0) 3 (30) .15
Flu-like symptoms 5 (12.5) 2 (6.7) 3 (30) .09
Urine output change 3 (7.5) 1 (3.3) 2 (20) .15
Stool color change 3 (7.5) 1 (3.3) 2 (20) .15
Rash/itching 2 (5.0) 0 2 (20) .06
Numbness or tingling 2 (5.0) 2 (6.7) 0 >.99
Fever >3 days 1 (2.5) 1 (3.3) 0 >.99
Jaundice 0 0 0 >.99
Bleeding/bruising 0 0 0 >.99
Other 13 (32.5) 10 (33.3) 3 (30) >.99
Number of ADEs
0 16 (40.0) 15 (50.0) 1 (10)
.03
1 8 (20.0) 6 (20.0) 2 (20)
2 7 (17.5) 4 (13.3) 3 (30)
3 1 (2.5) 1 (3.3) 0
4 1 (2.5) 0 1 (10)
5 3 (7.5) 2 (6.7) 1 (10)
6 2 (5.0) 2 (6.7) 0
7 2 (5.0) 0 2 (20)
Abbreviations: ADE, adverse drug event; LTBI, latent tuberculosis infection.
a Determined using t test for mean differences and Fisher exact test for frequency differences.
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Table 3. Characteristics of Patient (N = 40) Pharmacy Visits, by Patient Treatment Completion Status, Study on Using a Collaborative Care Model to Treat LTBI, New
Mexico, 2017–2018
Pharmacy Visit Characteristic Value
Completed Treatmenta
(n = 30)
Discontinued Treatment
(n = 10) P Valuea
Mean distance, mi (SD) 5.2 (3.1) 5.4 (3.4) 4.8 (1.8) .53
Distance to pharmacy, mi
≤5 25 (62.5) 18 (60.0) 7 (70)
.79>5 14 (35.0) 11 (36.7) 3 (30)
Unknown 1 (2.5) 1 (3.3) 0
Days between positive test and treatment start
0–60 16 (40.0) 10 (33.3) 6 (60)
.55
61–120 14 (35.0) 11 (36.7) 3 (30)
121–180 3 (7.5) 3 (10.0) 0
>180 4 (10.0) 4 (13.3) 0
Unknown 3 (7.5) 2 (6.7) 1 (10)
Initial visit time, min (SD) (n = 26) 25.0 (10.1) 25.3 (9.3) 24.4 (12.1) .84
Follow up visit time, min (SD) (n = 25) 22.0 (9.7) 23.75 (10.1) 18.9 (8.6) .24
Abbreviations: ADE, adverse drug event; LTBI, latent tuberculosis infection; SD, standard deviation.
a Determined using t test for mean differences and Fisher exact test for frequency differences. Values are no. (%) unless otherwise indicated.
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